DEPARTMENT OF HEALTH AND HUMAN SERVICES					
FOOD AN DISTRICT ADDRESS AND PHONE NUMBER	ID DRUG ADMINISTRATION DATE(S) OF INSPECTION				
1431 Harbor Bay Parkway	6/25/2018-6/27/2018				
Alameda, CA 94502-7070	FEI NUMBER				
(510) 337-6700 Fax: (510) 337-6702	3012289984				
(010)007 0700 Par. (010)007 0702					
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED					
Marcelino P. Casal, President/CEO					
FIRM NAME	STREET ADDRESS				
Well Care Discount Pharmacy, LLC	3300 W. Charleston Blvd., Suite A				
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED				
Las Vegas, NV 89102	Producer of Non-Sterile Drug Products				
hab vegab, NV obioz	TIOUROCI OF NON SECTIC BIRG TIOUROES				
action with the FDA representative(s) during the inspection o	ective action in response to an observation, you may discuss the objection or r submit this information to FDA at the address above. If you have any ess above.				
action with the FDA representative(s) during the inspection o questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED:	r submit this information to FDA at the address above. If you have any				
action with the FDA representative(s) during the inspection o questions, please contact FDA at the phone number and addre	r submit this information to FDA at the address above. If you have any				
action with the FDA representative(s) during the inspection o questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED:	r submit this information to FDA at the address above. If you have any ss above.				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1	r submit this information to FDA at the address above. If you have any ss above.				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1	r submit this information to FDA at the address above. If you have any ss above.				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spec Specifically,	r submit this information to FDA at the address above. If you have any ess above.				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spec Specifically, Your firm failed to reject Testosterone 2mg/gr	r submit this information to FDA at the address above. If you have any ess above.				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spec Specifically, Your firm failed to reject Testosterone 2mg/gr	r submit this information to FDA at the address above. If you have any ess above.				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spec Specifically, Your firm failed to reject Testosterone 2mg/gr potency testing results with a result of 126%,	r submit this information to FDA at the address above. If you have any ass above. This information to FDA at the address above. If you have any ass above. This information to FDA at the address above. If you have any ass above.				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spec Specifically, Your firm failed to reject Testosterone 2mg/gr potency testing results with a result of 126%, ^{(b) (4)} patients and your pharmacist was unable	r submit this information to FDA at the address above. If you have any ess above.				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spect Specifically, Your firm failed to reject Testosterone 2mg/gr potency testing results with a result of 126%, (^{b) (4)} patients and your pharmacist was unable	r submit this information to FDA at the address above. If you have any ass above. This are not rejected. The cream, lot 02092017:71@29 after you received poutside your range of (b) (4)%. This lot was distributed to				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spec Specifically, Your firm failed to reject Testosterone 2mg/gr potency testing results with a result of 126%, ^{(b) (4)} patients and your pharmacist was unable superpotent drug product.	r submit this information to FDA at the address above. If you have any ess above. difications are not rejected. cam cream, lot 02092017:71@29 after you received outside your range of (b) (4)%. This lot was distributed to to determine if the patients were notified of the				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spect Specifically, Your firm failed to reject Testosterone 2mg/gr potency testing results with a result of 126%, (^{b) (4)} patients and your pharmacist was unable superpotent drug product. In addition, your firm does not routinely perfor	r submit this information to FDA at the address above. If you have any ass above. ifications are not rejected. am cream, lot 02092017:71@29 after you received outside your range of (b) (4)%. This lot was distributed to to determine if the patients were notified of the rm potency testing on your drug products and has not				
action with the FDA representative(s) during the inspection of questions, please contact FDA at the phone number and addre DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Drug products failing to meet established spect Specifically, Your firm failed to reject Testosterone 2mg/gr potency testing results with a result of 126%, (^{b) (4)} patients and your pharmacist was unable superpotent drug product.	r submit this information to FDA at the address above. If you have any ass above. ifications are not rejected. am cream, lot 02092017:71@29 after you received outside your range of (b) (4)%. This lot was distributed to to determine if the patients were notified of the rm potency testing on your drug products and has not				

OBSERVATION 2

Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity.

Specifically,

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Ashar P Parikh, I	nvestigator	Ashar P Parikh Investgalor Signed By Ashar P, Parikh-S Dalle Signed B6-27-2018 14 22 00	DATE ISSUED 6/27/2018
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	ONS	PAGE 1 of 2 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION				
1431 Harbor Bay Parkway	6/25/2018-6/27/2018				
Alameda, CA 94502-7070	FEINUMBER				
(510)337-6700 Fax:(510)337-6702	3012289984				
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED					
Marcelino P. Casal, President/CEO					
FIRM NAME	STREET ADDRESS				
Well Care Discount Pharmacy, LLC	3300 W. Charleston Blvd., Suite A				
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED				
Las Vegas, NV 89102	Producer of Non-Sterile Drug Products				
Your firm received ^{(b) (4)} shipments of Domperidone BP lot $\#(b)$ (4) in (b) (4)					

2017. The Domperidone BP label states the bulk drug substance is "FOR VETERINARY USE ONLY." Your firm used lot #(b)(4) to produce ^{(b)(4)}- 20mg capsules on March 27, 2017 and June 27, 2017 and distributed to patients as part of prescriptions #(b)(6) and (b) (6).

OBSERVATION 3

Laboratory controls do not include determination of conformance to appropriate written specifications for the acceptance of each lot within each shipment of components used in the manufacture, processing, packing, or holding of drug products.

Specifically,

Your firm does not utilize compendial grade purified water for the production of drug products. For example, your firm utilizes non-compendial grade (b) (4)(b) (4) water purchased from (b) (4) stores to use in the production of drug products including but not limited to Dyclonine 1% Oral Solution as shown on the logged formula worksheet for lot #04202018:35@19 produced on 4/23/2018.

In addition, your firm has not performed any microbial testing on the store bought (b) (4) water.

SEE REVERSE	EMPLOYEE(S)SIGNATURE	Ashar P	
OF THIS PAGE	Ashar P Parikh, Inv	Investin	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 2 of 2 PAGES